Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

FTSE 100 dips as UK banks await capital rule easing; easyJet, ITV deals boost sectors; UK construction remains weak.

Market News
06 Jul 2026
Proactive Investors - Finance
View Source
Bearish
pluang ai news

The FTSE 100 fell 26 points to 10,653 amid declines in major stocks like AstraZeneca and Rolls-Royce, while easyJet and ITV saw gains due to takeover and sale deals. UK banks anticipate eased capital requirements from the Bank of England, potentially freeing cash for lending and dividends. The UK construction sector continues to struggle with subdued activity and price pressures despite slight PMI improvements. Meanwhile, England's World Cup win boosted UK high street footfall, benefiting hospitality stocks. Market watchers await upcoming US earnings and Federal Reserve minutes for further direction.

More News (AZN)

Lupus treatment improves with biologics, but many patients still face significant disease challenges.

Lupus treatment improves with biologics, but many patients still face significant disease challenges.

New research from Spherix Global Insights reveals that despite advances in lupus treatment, including increased use of biologics and new therapies, many patients with systemic lupus erythematosus (SLE) continue to experience persistent symptoms, freq...

Market News
Neutral
3 hours ago
FTSE 100 dips 40 points amid mixed sector moves; Microsoft cuts 4,800 jobs; ITV sells broadcast arm to Sky.

FTSE 100 dips 40 points amid mixed sector moves; Microsoft cuts 4,800 jobs; ITV sells broadcast arm to Sky.

The FTSE 100 fell 40 points to 10,639, with mixed sector performance as airlines and defence stocks gained while others like Primark owner AB Foods declined. Microsoft announced cutting 4,800 jobs to focus on growth priorities, causing a 1.7% drop in...

Market News
Neutral
1 day ago
Citi keeps AstraZeneca 'buy' ahead of Q2 results, eyeing late-stage drug trials as key catalyst

Citi keeps AstraZeneca 'buy' ahead of Q2 results, eyeing late-stage drug trials as key catalyst

Citi has maintained a 'buy' rating on AstraZeneca ahead of its Q2 earnings report due July 27, forecasting an 11% rise in earnings per share at constant exchange rates. The broker highlights upcoming phase three trial results for key drugs like Wainu...

Analyst Insights
Bullish
1 day ago
AI in Pathology market to nearly double by 2035 despite US-Israel-Iran conflict disruptions

AI in Pathology market to nearly double by 2035 despite US-Israel-Iran conflict disruptions

The global AI in Pathology market, valued at $28.75 million in 2025, is projected to grow at a 9.12% CAGR to reach $68.81 million by 2035. Growth is driven by rising demand for digital pathology, AI diagnostics, and improved workflow efficiency throu...

Market News
Neutral
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App